Filed Pursuant to Rule 424(b)(5)
Registration No. 333-264984-01
PROSPECTUS SUPPLEMENT
(To Prospectus Dated May 16, 2022)
Up to $300,000,000
IDACORP, Inc.
Common Stock
We may issue, offer and sell up to an aggregate of $300,000,000 of our common stock, no par value (“common stock”) from time to time through BofA Securities, Inc. (“BofA Securities”), J.P. Morgan Securities LLC (“J.P. Morgan”), Mizuho Securities USA LLC (“Mizuho”), Morgan Stanley & Co. LLC (“Morgan Stanley”), MUFG Securities Americas Inc. (“MUFG”), and Wells Fargo Securities, LLC (“Wells Fargo”), as our agents under an equity distribution agreement. We refer to BofA Securities, J.P. Morgan, Mizuho, Morgan Stanley, MUFG, and Wells Fargo collectively as the “sales agents.” The equity distribution agreement was entered into on May 20, 2024 (the “equity distribution agreement”). The equity distribution agreement provides that, in addition to the issuance and sale of shares of our common stock by us through the applicable sales agent, we also may enter into forward sale agreements under a separate master forward sale confirmation and related supplemental confirmation between us and such sales agent or its affiliate, which we refer to as the forward counterparty. In connection with each forward sale agreement, the relevant forward counterparty (or its affiliate) will, at our request, attempt to borrow from third parties and, through the relevant sales agent, sell a number of shares of our common stock equal to the number of shares of our common stock that underlie the forward sale agreement to hedge the forward sale agreement. We entered into master forward sale confirmations with each of the forward counterparties on May 20, 2024.
In no event will the aggregate number of shares of our common stock sold through the sales agents, as our agents and as, or on behalf of, the forward counterparties, under the equity distribution agreement have an aggregate gross sales price in excess of $300,000,000. The offering of our common stock pursuant to the equity distribution agreement will terminate upon the earliest of (1) the sale, under the equity distribution agreement, of shares of our common stock with an aggregate gross sales price equal to $300,000,000 and (2) the termination of the equity distribution agreement, pursuant to its terms, by us, the sales agents, or the forward counterparties.
We will not initially receive any proceeds from the sale of borrowed shares of our common stock by a forward counterparty or its related sales agent, as applicable. We expect to receive proceeds from the sale of shares of our common stock upon future physical settlement of the relevant forward sale agreement with the relevant forward counterparty on dates specified by us on or prior to the maturity date of the relevant forward sale agreement. If we elect to cash settle or net share settle under a forward sale agreement, we may not (in the case of cash settlement) or will not (in the case of net share settlement) receive any proceeds, and we may owe cash (in the case of cash settlement) or shares of our common stock (in the case of net share settlement) to the relevant forward counterparty.
The shares of our common stock to which this prospectus supplement relates may be offered and sold by any method permitted by law to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including by means of ordinary brokers’ transactions on the New York Stock Exchange, the existing trading market for our shares of common stock, or otherwise at market prices prevailing at the time of sale, or sales made to or through a market maker or through an electronic communications network. In addition, shares of our common stock may be offered and sold by such other methods, including privately negotiated transactions (including block trades), as we and any sales agent agree to in writing. The sales agents are not required to sell any specific number or dollar amount of shares of our common stock, but each of them and the forward counterparty, as applicable, will use its commercially reasonable efforts to sell shares designated by us in accordance with the equity distribution agreement. The sales agents will not engage in any transactions that stabilize our common stock. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.
We will pay each sales agent a commission of up to 1.250% of the sales price of all shares of our common stock sold through it as our sales agent under the equity distribution agreement. The commission we pay to any sales agent for sales by privately negotiated transactions (including block trades) or other methods may vary, as we and any sales agent agree to in writing. The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory or self-regulatory organization in connection with the sales, will be our net proceeds for the sale of the shares. In connection with each forward sale agreement, the relevant forward counterparty will receive, reflected in a reduced initial forward sale price payable by the relevant forward counterparty under its forward sale agreement, a commission of up to 1.250% of the volume weighted average of the sales prices of all borrowed shares of our common stock sold during the applicable period by it (or its related sales agent, as applicable) as a forward counterparty.
We list our common stock on the New York Stock Exchange under the symbol “IDA”. On May 17, 2024, the last reported sale price of our common stock on the New York Stock Exchange was $98.47 per share.
Investing in our common stock involves risks. See “Risk Factors” beginning on page S-8 of this prospectus supplement to read important factors you should consider before investing in our common stock.
Neither the Securities and Exchange Commission (the “SEC”) nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
| | | | |
BofA Securities | | J.P. Morgan | | Mizuho |
| | |
Morgan Stanley | | MUFG | | Wells Fargo Securities |
The date of this prospectus supplement is May 20, 2024